Gisela Terwindt, MD, PhD, Leiden University, Leiden, Netherlands, expresses her excitement on new data and ongoing studies showing which patients will benefit the most from CGRP inhibitors. Prof. Terwindt is hopeful that we will be able to develop new preventative migraine treatment strategies for patients. The importance of studying genomics, metabolomics, and proteomics in other neurological diseases is also highlighted to achieve a better understanding of the -omics field in migraine. This interview took place during the International Headache Congress 2021.